The MedTech M&A market has demonstrated remarkable resilience despite a period of macroeconomic uncertainty. However, the growth drivers of today look significantly different from those making waves during the pandemic era. A&M's Life Sciences team highlights trends, challenges, and strategies for the MedTech mergers and acquisitions (M&A) landscape, offering predictions for 2025 and beyond.
This report includes:
- Analysis of the shifting landscape of MedTech M&A in the post-pandemic era
- Strategic insights around how leading companies are leveraging M&A to drive competitive advantage
- Recommendations for both acquirers and targets
- Our predictions for M&A trends in the industry
Dive into the future of MedTech M&A and stay ahead of the curve in this rapidly evolving sector.
Download the Report
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
